SPPAM
ANIP icon

Summit Partners Public Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Summit Partners Public Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-96,910
Closed -$4.47M – 121
2021
Q4 		$4.47M Buy
+96,910
New +$4.16M 0.17% 94

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Summit Partners Public Asset Management's ANIP Position: Q1 2022 in Review

Summit Partners Public Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2022, closing a stake of 96,910 shares — an estimated $4.47M sold.

Summit Partners Public Asset Management first reported a position in ANIP in Q4 2021 and held it in 1 quarter. The position peaked at $4.47M in Q4 2021. 126 funds tracked by Wall St. Rank hold ANIP as of Q1 2022.

  • Summit Partners Public Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 96,910 ANI Pharmaceuticals shares in Q1 2022, an estimated $4.47M.
  • Summit Partners Public Asset Management first reported a position in ANI Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Summit Partners Public Asset Management's ANI Pharmaceuticals position peaked at $4.47M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2022.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2022, filed 16 May 2022.